US FDA grants breakthrough therapy designation to Daiichi Sankyo & AstraZeneca’s Enhertu plus pertuzumab to treat ...
Enhertu (fam-trastuzumab deruxtecan-nxki) in combination with pertuzumab has been granted Breakthrough Therapy Designation (BTD) in the US for the first-line treatment of adult patients with unresectable or metastatic HER2 positive breast cancer. Enhertu …